Login / Signup

Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections.

Elizabeth A EdmistonTaissa A BejBrigid M WilsonRobin L P JumpJoy A Phillips
Published in: Therapeutic advances in infectious disease (2023)
The known survival benefits of donepezil were retained but not found to be specific to COVID-19 among people with Alzheimer's disease.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • coronavirus disease
  • chronic kidney disease
  • sars cov
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes
  • patient reported